Download fatovich_amphetamine.aspx

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Pharmacokinetics wikipedia , lookup

Drug interaction wikipedia , lookup

Medication wikipedia , lookup

Bad Pharma wikipedia , lookup

Prescription costs wikipedia , lookup

Psychopharmacology wikipedia , lookup

Polysubstance dependence wikipedia , lookup

Prescription drug prices in the United States wikipedia , lookup

Pharmaceutical industry wikipedia , lookup

Pharmacognosy wikipedia , lookup

Amphetamine wikipedia , lookup

Stimulant wikipedia , lookup

Transcript
Media release
Australia’s amphetamine usage amongst highest in world, associated with mental health problems
Amphetamines are the most commonly used illicit drugs after cannabis, and Australia has one of the highest
rates of their usage in the world
There is good evidence that usage is associated with poor mental health and a range of other health problems.
A nine- year study by Professor Daniel Fatovich and colleagues from the University of Western Australia and
Curtin University of Technology has found that amphetamine-related presentations to the emergency
department are “associated with a significant cluster of hospitalisations around that episode, most prominently
for psychiatric diagnoses.”
They are calling for public education and counselling to advocate less risky behaviour in order to decrease the
burden of illness.
The study, published in the latest issue of Emergency Medicine Australasia, the journal of the Australasian
College for Emergency Medicine, examined records of 138 patients who had 156 amphetamine-related
presentations.
Their most common diagnosis was mental disorders, followed by injury and poisoning.
The mean age was 28 years, 71% were male, and over half used amphetamines at least weekly.
Thirty-nine per cent required admission to hospital.
Professor Fatovich said there have been changing patterns of drug usage over time.
In Australia the peak of heroin availability and use occurred around 1998–1999. This was followed by a
shortage known as the “heroin drought” and a rise in amphetamine use, which peaked around 2005.
This was followed by a mixed picture of both amphetamine and heroin use.
More recently, it has been reported that amphetamine use has increased, and the drug was easy to obtain.
“We have previously reported a 10-year record linkage study of morbidity associated with heroin overdose
presentations to an ED.
“This found that non-fatal heroin overdose ED presentations are associated with a cluster of hospitalisations
around that episode, likely to be related to heroin availability.
“Given the extent and consequences of use of amphetamines, surprisingly little attention has been given to
examining their impact on health services.”
Professor Fatovich said amphetamine use has been associated not just with mental health problems but also
with a growing number of deaths.
“An examination of amphetamine-related deaths in Taiwan from 1990 to 2007 found a six-fold risk of mortality
compared with the general population.
“In Australia a review of the National Coroners Information System from July 2000 to June 2005 identified 371
amphetamine fatalities.”
In the present study four people (2.9%) died within two years of attending the ED with an amphetamine-related
presentation.
No toxicology reports were available for these cases and it is not known whether other drugs were involved,
but polydrug use is common among illicit drug users, Professor Fatovich said.
Amphetamine users have frequent contact with the healthcare system through ED presentations and hospital
admissions.
“This provides multiple opportunities for brief interventions, such as giving advice or counselling on reducing or
ceasing drug use.”
FURTHER INFORMATION
Professor Daniel Fatovich, phone 0409 103 818
Issued for the Australasian College for Emergency Medicine (03 9320 0444) by Marilyn Bitomsky, 07 3371
3057 or 0412 884 114.